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ABSTRACT 
Objective: Momordica charantia fruit extract and antidiabetic drug Nateglinide might be used simultaneously in the treatment of diabetes, so the 
objective of this study was to investigate pharmacokinetic herb-drug interactions of Momordica charantia fruit extract and pure charantin with 
nateglinide in rats. 
Methods: After oral co-administration of Momordica charantia fruit extract (250 mg/kg) and Charantin (10 mg/kg) with nateglinide in rats, drug 
concentration parameters peak plasma concentration (Cmax), time to reach peak plasma concentration (tmax), elimination half-life (t1/2), apparent 
volume of distribution (Vd), plasma clearance (Cl), and area under the curve (AUC) were calculated by using the non-compartment model. 
Results: NAT was absorbed into the circulatory system and reached its peak concentration approximately 2 h after being administered individually. 
tmax of groups co-administered NAT+MCE has been changed to 4h. A significant decrease in Cmax of NAT from 16.28 µg/ml to 11.37 µg/ml and 10.37 
µg/ml with NAT with charantin and NAT with MCE groups, respectively. AUC of NAT decreased from 84.53 h/µg/ml to 53.63 h/µg/ml and 47.17 
h/µg/ml by co-administration with Charantin and MCE respectively. Co-administration of nateglinide with Charantin and Momordica charantia fruit 
extract decreased systemic exposure level of nateglinide in vivo with decreasing Cmax and AUC and an increase in t1/2, Cl and Vd.  
Conclusion: From this study, it can be concluded that nateglinide, Momordica charantia fruit extract, and pure Charantin existed pharmacokinetic 
herb-drug interactions in the rat which has to be correlated with the anti-diabetic study. Further studies should be done to understand the effect of 
other herbal ingredients of Momordica charantia fruit extract on nateglinide as well as to predict the herb-drug interaction in humans. 
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amino]propanoic acid.) (NAT fig. 1) belongs to class of meglitinide 
used in the treatment of diabetes [1–3]. Momordica charantia (MC) 
is a part of the cucurbitaceae family. It grows in tropical areas of 
India, Amazon, East Africa, Asia, and South America. MC contains a 
collection of biologically active chemicals, including alkaloids, 
saponins, flavonoids, triterpenes, proteins, and acids. The plant 
possesses anti-tumorous hypoglycemic, anti-bacterial, anti-parasitic, 
anti-viral, anti-fertility, and anti-carcinogenic properties. Fruits are 
used as a traditional medication for the treatment of diseases like 
illness of the liver, worms, colic spleen, rheumatism, gout, and also 
useful in the treatment of diabetes and cancer. It is a potent 
hypoglycemic agent due to the presence of insulin and alkaloids like 
a mixture of steroidal sapogenins and peptides known as charantin. 
MC is the most common plant used as anti-diabetic [4-7]. Charantin 
(fig. 1), an active constituent in the fruits of this medicinal plant, has 
been reported to have potential hypoglycemic activity [8]. 
Many polyherbal formulations, consisting of charantin as the main 
ingredient as anti-diabetic, are available in local Indian markets. In 
the treatment of diabetes, it is common practice that herbal 
formulations are either taken with or without the knowledge of 
health care providers, by the patients for good therapeutic effects. 
This may lead to either useful or toxic effects. Increasing 
consumption of medicinal herbs, which are often administered in 
combination with conventional therapeutic drugs, constituents in 
herbal preparations may be substrates, inhibitors, or inducers of 
cytochrome P450 enzymes (CYPs) and have an impact on the 
pharmacokinetics and pharmacodynamics of any co-administered 
drugs metabolized by this system [9]. Many studies reported for 
interaction between Momordica charantia extract (MCE) with 
various synthetic drugs [10-13]. Unfortunately, not a single attempt 
has been done to investigate the interaction study of MC and it's one 
of the major constituent Charantin with NAT, after oral 
administration in rats. Previously reported literature is present for 
the bioanalytical method for determining NAT in rats and humans 
[14-18]. However, there is no analytical method is available for 
simultaneous estimation of Charantin and NAT. Prompted by the 
above findings, an attempt to develop a new validated HPLC method 
for simultaneous determination of Charantin and NAT in rat plasma 
and application of the developed method for pharmacokinetic study 
in rats has been done. The study aimed to investigate the herb-drug 
interactions of MCE and Charantin with NAT by comparing their 
pharmacokinetic profiles after oral administration in rats. 
MATERIALS AND METHODS 
Chemicals and reagents 
Plant extract 
MCE was purchased from Green Heaven Pvt. Ltd, Nagpur (Batch 
No.:FG/BME/130417/1). All the tests like identification, moisture, 
acid-insoluble ash, bulk density, tapped bulk density, heavy metals, 
microbiology test, residual solvent analysis, pesticide residue 
analysis, and phytochemical analysis were within limits. 
Chemicals 
Charantin was purchased from Green Heaven Pvt. Ltd, Nagpur; 
Nateglinide and Repaglinide were procured from Yarrow Chem. 
Products, Mumbai. 
Animals 
Six female Wistar rats weighing 180–200 gm were purchased from 
the National Institute of Biosciences. The rats were kept in room 
temperatures (25±2 ᵒC) with 12 h night cycles (12h/12h). The 
animals had free access to food and water. After acclimatization for 
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7 d’ animals were fasted overnight (12 h) before each experiment. 
All experiments were performed as per the guidelines of CPCSEA 




A       B 
Fig. 1: Chemical structures of Charantin (A) and Nateglinide (B) 
 
In vivo pharmacokinetic study in rats 
Drug administration and blood sampling 
Experimental animals were divided into three groups of 18 animals 
of each as follows. Oral administration of Group 1-NAT alone (10 
mg/kg, p. o.), Group 2-co-administration of Charantin with NAT (10 
mg/kg+10 mg/kg, p. o.) and Group 3-co-administration of MCE with 
NAT (250 mg/kg+10 mg/kg, p. o.) for 7 d. After drug administration, 
18 animals were further subdivided into three groups with six 
animals each. Blood samples (1 ml each) were collected at 0, 1.5, 4, 
and 10 h in the first subgroup, 0.5, 2, 6, and 12 h in the second 
subgroup, and 1, 3, 8, and 24 h in the third subgroup. Only four 
blood samples were collected from the individual animal within 24 h 
from the retro-orbital plexus under light ether anesthesia. The 
samples were transferred to EDTA tubes and centrifuged at 15000 
rpm for 20 min. Plasma was separated from the blood and stored at 
−80 °C until further analysis. 
Sample preparation 
10μl of each solution of Charantin and NAT added into 400μl drug-
free plasma separately. For each calibration standard, 10μl of 
internal standard (I. S.) Repaglinide (250μg/ml) solution was added 
and vortexed for 2 min. 1.5 ml of ethyl acetate was added to each 
calibration standard and vortexed for 2 min. After centrifugation at 
15000 rpm for 30 min, the supernatant was transferred to another 
prelabelled polypropylene tubes and the solvent evaporated to 
dryness under a gentle stream of nitrogen gas at 35˚C. The residue, 
reconstituted with 200μl of mobile phase, and a 20μL aliquot, was 
injected into the High-Performance Liquid Chromatography (HPLC) 
system for analysis. The quality control (QC) samples also prepared 
in the same manner at concentrations of 1, 10, and 50 μg/ml as a 
single batch at each concentration. 
HPLC analysis 
The chromatographic separation was performed using an HPLC 
binary gradient system equipped with an autosampler system and 
a UV detector UV-3000-M with a Grace C18 column (250 mm x 
4.6ID, Particle size: 5 µm). The mobile phase system was 
optimized to give a good resolution of Charantin, NAT, and 
Repaglinide (I. S.) from other endogenous substances in the 
plasma sample. The mobile phase consisted of the mixture of 
solvent A (Methanol), solvent B (10 mmol Phosphate Buffer) in the 
ratio of 80:20 (v/v) for 18 min at a flow rate of 1 ml/min. The NAT, 
Charantin, and I. S. were detected at 7.5, 9.7, and 12.8 min, 
respectively (fig. 2). The concentration of Charantin was 
determined using the peak area ratio of pure Charantin to I. S. The 
concentration of Charantin in MCE was determined using the peak 
area ratio of Charantin in MCE and I. S. Similarly, the concentration 
of NAT was determined using the peak area ratio of NAT and I. S. 
Further validation of the method was done according to the US 
Food and Drug Administration (USFDA) guidelines for selectivity, 
matrix effects, recovery, and stability [19]. 
Data analysis 
Data analysis performed using Graph Pad Prism version 7.04 (Graph 
Pad Software Inc., USA). The peak plasma concentration (Cmax) and 
time reaching Cmax (tmax) read directly from the observed individual 
plasma concentration-time data. All data expressed as 
mean±Standard error of the mean (SEM). Differences between 
groups were evaluated by two-way Analysis of variance (ANOVA) 
(Bonferroni test). The differences are considered significant at 
*P<0.05. 
RESULTS 
The developed HPLC method was validated as per USFDA guidelines. 
Typical equations of the calibration curves of Charantin and NAT 
obtained y = 0.0384x+0.2751 and y = 0.0538x+0.3758 respectively 
with good correlation coefficient (r2= 0.9923 and 0.9991 
respectively). Intra and inter batch precisions within limits (R. SD ˂ 
15 %) and accuracy was in between the range, 85 to 115 %. The 
developed HPLC method was applied successfully to the 
pharmacokinetic study in the rat plasma for the respective groups. 
The mean plasma concentration-time curves are shown in fig. 3 and 
the pharmacokinetic parameters are shown in table 1. NAT 
absorbed into the circulatory system and reached its peak 
concentration approximately 2 h after administered individually. tmax 
of groups co-administered NAT+Charantin was the same, but tmax of 
group co-administered NAT+MCE has been changed to 4h, 
respectively. A significant decrease in Cmax of NAT from 16.28 µg/ml 
to 11.37 µg/ml and 10.37 µg/ml with NAT with charantin and NAT 
with MCE groups, respectively. AUC of NAT decreased from 84.53 
h/µg/ml to 53.63 h/µg/ml and 47.17 h/µg/ml by co-administration 
with Charantin and MCE, respectively. Fast elimination of NAT was 
observed with increased t1/2 from 9.18 to 11.72 h, Vd, from 0.11 to 
0.37 L and Cl from 0.08 to 0.22 L/h when co-administered with 
Charantin. Whereas t1/2 of NAT increased from 9.18 up to 11.80 h, Vd 
from 0.11 to 5.51 L and Cl from 0.08 to 0.32 L/h when co-
administered with MCE. Co-administration of NAT with Charantin 
significantly (P ˂ 0.05) decreased the Cmax, tmax, Area Under the Curve 
(AUC), Elimination rate constant (Ke) and increased the elimination 
half-life (t1/2), apparent volume of distribution (Vd), and plasma 
clearance (Cl) of NAT when compared to NAT alone group. Co-
administration of NAT with MCE significantly (P ˂ 0.05) decreased 
the Cmax, AUC, Ke and increased the tmax, t1/2, Cl, and Vd of NAT when 
compared to NAT alone group. These results indicated slow 
metabolism for nateglinide and a better volume of distribution has 
been achieved in the combination groups. 
Where oral administration of, 
Group 1-NAT alone (10 mg/kg, p. o.), 
Group 2-co-administration of NAT (10 mg/kg, p. o.) with Charantin 
(10 mg/kg, p. o.) and 
Group 3-co-administration of NAT (10 mg/kg, p. o) with MCE (250 
mg/kg, p. o.). 
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Fig. 2: Chromatogram of (A) blank plasma sample (B) blank plasma sample with Repaglinide (I. S.) (C) plasma sample spiked with NAT (10 
μg/ml), Charantin (10 μg/ml) and I. S. (D) a plasma sample obtained from a rat at 2 h after oral administration of 10 mg of Charantin and 
10 mg of NAT, Where I. S. = Internal standard, μg/ml = microgram per milliliter 
 
 
Fig. 3: Mean concentration-time curves of NAT (10 mg/kg, p. o.) alone, after co-administration of Charantin (10 mg/kg+10 mg/kg, p. o.) 
and after co-administration with MCE (10 mg/kg+250 mg/kg, p. o.), Where mg/kg= milligram per kilogram, p. o. = by mouth 
 
Table 1: Results of pharmacokinetic parameters of all the experimental groups 
 Parameters  NAT alone group 1 NAT+Charantin group 2 NAT+MCE  group 3 
Cmax (µg/ml)  16.28±0.27 11.37±0.305 10.37±0.311 
tmax (h) 2 2 4 
AUC (h/µg/ml) 84.53±0.628 53.63±0.641 47.17±0.674 
Ke (1/h) 0.075±0.032* 0.059±0.028* 0.058±0.023* 
t1/2 (h) 9.18±0.052 11.72±0.047* 11.80±0.043* 
Vd (L) 0.11±0.04* 0.37±0.04* 5.51±0.11 
Cl (L/h) 0.08±0.05 0.22±0.03* 0.32±0.00* 
Data are expressed as mean±SD; n=6 rats per group. One-way ANOVA followed by Dunnett’s test. *P<0.05, when group 2 and 3 compared to group 
1., Where μg/ml = microgram per milliliter, h = hour, h/µg/ml= hour per microgram per milliliter, 1/h = litre per hour, L= Litre. SD= Standard 
deviation, ANOVA= Analysis of variance, n = number. 
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DISCUSSION 
MC (Cucurbitaceae) has been used for the treatment of Diabetes. 
Various herb-drug interaction studies of MCE with antidiabetic 
drugs metformin, glibenclamide in diabetic rats and mice have been 
reported previously [8-11]. Charantin is the main the lead 
compound in MCE. Charantin and MCE are used for diabetes. 
Pharmacokinetic drug food interaction study of Nateglinide and 
Pomegranate Fruit Juice has been reported previously [20]. Also, the 
effect of Cilostazol, a CYP2C9 inhibitor, on pharmacokinetics of 
Nateglinide in wistar rats has been reported [21]. Not a single article 
is available for the pharmacokinetic interaction of Nateglinide with 
MCE and Charantin. This research work is the first attempt to study 
the pharmacokinetic interaction of Nateglinide with MCE and 
Charantin in wistar rats. 
NAT is metabolized by the microsomal enzyme CYP2C9, whereas 
MCE is an inhibitor of the CYP2C9 enzyme. By inhibiting metabolism, 
MCE can increase the activity of NAT. Thus, the hypothesis that any 
substance influencing the CYP2C9 enzyme affects the metabolism of 
NAT in rats, which should be studied.  
As per hypothesis, pharmacokinetic interactions were found by a 
significant decrease in Cmax of NAT from 16.28 µg/ml to 11.37 µg/ml 
and 10.37 µg/ml with NAT with charantin and NAT with MCE groups, 
respectively. Decrease in AUC of NAT was observed from 84.53 
h/µg/ml to 53.63 h/µg/ml and 47.17 h/µg/ml by co-administration 
with Charantin and MCE, respectively. Fast elimination of NAT was 
observed with increased t1/2 from 9.18 to 11.72 hr, Vd from 0.11 to 
0.37 L and Cl from 0.08 to 0.22 L/h when co-administered with 
Charantin. Whereas t1/2 of NAT increased from 9.18 up to 11.80 h, Vd 
from 0.11 to 5.51 L and Cl from 0.08 to 0.32 L/h when co-administered 
with MCE. Co-administration of NAT with Charantin and MCE 
decreased the systemic exposure level of NAT in vivo, with decreasing 
Cmax and AUC, but increased t1/2 is significantly more with NAT+MCE 
treated group compared to NAT+Charantin treated group. These 
results indicated slow metabolism for NAT and a better volume of 
distribution has been achieved in the combination group.  
Previously food-drug and drug-drug interactions of NAT have been 
reported and in results, it was observed that Cmax and AUC of NAT 
were increased after co-administration with pomegranate juice, 
whereas Cmax of NAT was decreased and no significant change in AUC 
of NAT was observed after co-administration with cilostazol. 
Consequence of CYP inhibition is an increase in the plasma 
concentration of the parent drug. Previous studies also reported 
increases in AUCs with co-administration of drugs inhibiting CYP 
isoenzymes exceeded up to 50% for nateglinide [22-23]. NAT is 
metabolized majorly by the microsomal enzyme CYP2C9 and to a 
lesser extent via CYP3A4. Based on results of this study and previous 
literature, other cytochromes, P-gp levels, components in MCE and 
various genotypic and phenotypic factors might be interfering with 
the metabolism, which should be studied further [24]. 
We hypothesized that co-administration of MCE or Charantin may 
affect the CYP450 family of enzymes and a herb-drug interaction will 
impact the pharmacokinetics of NAT. However, further study is 
needed to establish interactions in humans. 
CONCLUSION 
In conclusion, the results obtained from the study suggested that 
NAT with MCE and pure Charantin existed pharmacokinetic herb-
drug interactions in the rat. A significant decrease in Cmax, AUC, and 
increase in t1/2, Vd, Cl of NAT was observed after co-administration 
with pure Charantin and MCE. In anti-diabetic studies, even though 
the dose of Charantin is equal in both groups treated with MCE and 
Charantin, there was better activity observed with MCE treated 
group. The study observed that co-administration of Charantin and 
MCE changes the pharmacokinetics of NAT. Further studies should 
be done to understand the effect of other herbal ingredients of MCE 
and various genotypic and phenotypic factors on NAT, as well as to 
predict the herb-drug interactions in humans. Physicians and 
patients using MC should know its possible herb-drug interaction 
with NAT. The study provided valuable information for the rational 
use of herbal remedies in the treatment of diabetes. 
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